Weight Loss Giants Going Head-to-Head; FDA OKs Omnipod GO; GLP-1 Drugs for Wolfram?

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, 榴莲视频 April 25, 2023

Endo Break over a computer rendering of a man with illustrated body organs.

Eli Lilly plans to test its diabetes drug and tirzepatide (Mounjaro) in a head-to-head trial against Novo Nordisk's semaglutide (Wegovy). (Endpoints News)

One extreme risk of semaglutide for weight loss: . (New York Times)

The , a tubeless, basal-only insulin pump for adult patients with type 2 diabetes typically using daily injections of long-acting insulin, said maker Insulet.

Missouri is slated to become the first state to in adults. (NPR)

The Endocrine Society threw its support behind a new for people with private insurance.

As part of a $1 billion deal, Eli Lilly is selling its to Amphastar Pharmaceuticals. (Reuters)

"I couldn't bring myself to join in the applause surrounding Lilly's announcement," said Leemore S. Dafny, PhD, of Harvard University in Boston, in a perspective piece on the recent insulin price cuts.

Could GLP-1 receptor agonists help patients with the rare condition ? (Diabetologia)

A $4.1 million NIH grant was awarded to to dive deeper into why kids develop type 2 diabetes.

Soda, lemonade, and other sugary drinks were in people with type 2 diabetes. (The BMJ)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she鈥檚 worked at the company since 2015.